Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43846   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-002993-19
    Sponsor's Protocol Code Number:54767414MMY3010
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-01-28
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2015-002993-19
    A.3Full title of the trial
    An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent
    Un protocollo per l'uso del trattamento in aperto con daratumumab in soggetti con mieloma multiplo che hanno ricevuto almeno 3 precedenti linee terapeutiche (tra cui un inibitore del proteasoma e un agente immunomodulatore) o che presentano una doppia refrattariet¿ all'inibitore del proteasoma e all'agente immunomodulatore
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Early Access Treatment with Daratumumab for (Relapsed or Refractory) Multiple Myeloma
    Trattamento di accesso precoce con Daratumumab per Mieloma Multiplo (recidivato o refrattario)
    A.3.2Name or abbreviated title of the trial where available
    Early Access Treatment with Daratumumab for (Relapsed or Refractory) Multiple Myeloma
    Trattamento di accesso precoce con Daratumumab per Mieloma Multiplo (recidivato o refrattario)
    A.4.1Sponsor's protocol code number54767414MMY3010
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJANSSEN CILAG INTERNATIONAL NV
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJANSSEN CILAG SPA
    B.4.2CountryItaly
    B.4.1Name of organisation providing supportIANSSEN CILAG INTERNATIONAL NV
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationJanssen-Cilag International N.V.
    B.5.2Functional name of contact pointClinical Registry group
    B.5.3 Address:
    B.5.3.1Street AddressArchimedesweg 29
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333
    B.5.3.4CountryNetherlands
    B.5.4Telephone number0031715242166
    B.5.5Fax number0031715242110
    B.5.6E-mailClinicalTrialsEU@its.jnj.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/13/1153
    D.3 Description of the IMP
    D.3.1Product nameDaratumumab
    D.3.2Product code HuMax-CD38
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeanticorpo monoclonale umano
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Multiple myeloma
    Mieloma multiplo
    E.1.1.1Medical condition in easily understood language
    Multiple myeloma
    Mieloma multiplo
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10028228
    E.1.2Term Multiple myeloma
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The objective of this study is to provide early access to daratumumab treatment and collect additional
    safety data while the medication is not commercially available for subjects with multiple myeloma who
    have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an
    immunomodulatory agent (IMiD) or whose disease is double refractory to both a PI and an IMiD.
    L'obiettivo di questo studio ¿ fornire accesso precoce al trattamento con daratumumab e raccogliere dati aggiuntivi sulla sicurezza mentre il farmaco non ¿ ancora disponibile in commercio per i soggetti con mieloma multiplo che hanno ricevuto almeno 3 precedenti linee terapeutiche tra cui un inibitore del proteasoma (PI) e un agente immunomodulatore (IMiD) o la cui malattia ¿ refrattaria sia a un PI che a un IMiD.
    E.2.2Secondary objectives of the trial
    There is no hypothesis associated with this objective.
    Non ci sono ipotesi associate a questo obiettivo
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Subject must be at least 18 years of age
    - Subject must have documented multiple myeloma and have evidence of disease progression on or after the most recent prior treatment regimen as defined by IMWG criteria:
    Subjects who have received at least 3 prior lines of therapy including a proteasome inhibitor (greater than or equal
    to [>=] 2 cycles or 2 months of treatment) and an IMiD (>= 2 cycles or 2 months of treatment) in any order during the course of treatment (except for subjects who discontinued either of these treatments due to a severe allergic reaction within the first 2 cycles/months)
    OR
    Subjects whose disease is double refractory to a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD). For subjects who have received more than 1 type of PI, their disease must be refractory to the most recent one. Similarly, for those who have received more than 1 type of IMiD, their disease must be refractory to the most recent one
    - Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1,or 2
    - A woman of childbearing potential must have a negative serum or urine pregnancy test at Screening
    - A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control during the study, and all men must also not donate sperm during the study and for 6 months after receiving the last dose of study drug
    -Il soggetto deve avere almeno 18 anni.
    -Il soggetto deve presentare un mieloma multiplo documentato ed evidenza di malattia in progressione contestualmente a o dopo il regime di trattamento precedente più recente in base ai criteri IMWG :
    • Soggetti che hanno ricevuto almeno 3 linee terapeutiche precedenti tra cui un inibitore del proteasoma (= 2 cicli o 2 mesi di trattamento) e un IMiD (= 2 cicli o 2 mesi di trattamento) in un qualsiasi ordine nel corso del trattamento (tranne per soggetti che hanno interrotto uno dei trattamenti a causa di una grave reazione allergica entro i primi 2 cicli/mesi).

    OPPURE
    • Soggetti con doppia refrattarietà della malattia a un PI e un IMiD. Per i soggetti che hanno ricevuto più di un tipo di PI, la malattia deve essere refrattaria al più recente. In modo analogo, per i soggetti che hanno ricevuto più di un tipo di IMiD, la malattia deve essere refrattaria al più recente.

    -Il soggetto deve presentare un punteggio dello stato di performance ECOG pari a 0, 1 o 2
    -Le donne in età fertile devono presentare un test di gravidanza sul siero o sulle urine con risultato negativo allo screening.
    -Un uomo che è sessualmente attivo con una donna in età fertile e che non è stato sottoposto a vasectomia deve acconsentire a usare un metodo contraccettivo a barriera (ad es. o un profilattico con schiuma/gel/film/crema/supposta spermicida o la partner deve indossare un cappuccio occlusivo [diaframma o cappuccio cervicale] con schiuma/gel/film/crema/supposta spermicida) durante lo studio; inoltre tutti gli uomini non devono donare sperma durante lo studio e per 6 mesi dopo l'ultima dose del farmaco sperimentale.
    E.4Principal exclusion criteria
    - Ever enrolled in another daratumumab study or eligible for enrollment in another ongoing clinical study of daratumumab
    - Subject receives any other anti-myeloma therapy while receiving daratumumab
    - Enrolled in another interventional clinical study with therapeutic intent
    - Subject has known chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) less than 50% of predicted normal
    - Subject has known moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification
    - Prior exposure to any anti-CD38 monoclonal antibody
    -Arruolamento in un altro studio di daratumumab o idoneità all'arruolamento in un altro studio clinico in corso su daratumumab.
    -Somministrazione di un'altra terapia anti-mieloma durante l'assunzione di daratumumab
    -Arruolamento in un altro studio clinico interventistico con intento terapeutico.
    -Presenza di COPD nota con un volume espiratorio forzato in 1 secondo (FEV1) <50% del valore normale previsto.
    -Storia di asma persistente moderata o grave negli ultimi due anni o asma incontrollata di qualsiasi classificazione in atto
    -Precedente esposizione a un qualsiasi anticorpo monoclonale anti-CD38
    E.5 End points
    E.5.1Primary end point(s)
    Safety
    Sicurezza
    E.5.1.1Timepoint(s) of evaluation of this end point
    Not Applicable
    Non Applicabile
    E.5.2Secondary end point(s)
    Not applicable
    E.5.2.1Timepoint(s) of evaluation of this end point
    Not applicable
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned15
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA58
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Russian Federation
    United States
    Belgium
    Italy
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Enrolled subjects will be transitioned from study drug to commercial
    product once commercial product is available (or when daratumumab
    can be accessed from another source)
    I pazienti arruolati passeranno dal farmaco sperimentale al prodotto commerciale quando lo stesso sar¿ disponibile in commercio (o quando il Daratumumab sar¿ accessibile da una fonte alternativa)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1060
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 940
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state70
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 280
    F.4.2.2In the whole clinical trial 2000
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Enrolled subjects will be transitioned from study drug to commercial product once commercial product is available (or when daratumumab can be accessed from another source)
    I pazienti arruolati passeranno dal farmaco sperimentale al prodotto commerciale quando lo stesso sar¿ disponibile in commercio (o quando il Daratumumab sar¿ accessibile da una fonte alternativa)
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-02-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-02-09
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-08-02
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 15:12:18 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA